Effects of Low-Dose Atorvastatin on the Peripheral Blood Mononuclear Cell Secretion of Angiogenic Factors in Type 2 Diabetes

Figures

• 

  Figure 1. VEGF level in the supernatant from a culture of human PBMCs isolated from statin-treated or statin-free type 2 diabetic patients, or from non-diabetic controls in the medium only, or preincubated with glucose (ANOVA). *—statistically significant difference compared with other groups at basic conditions, for p ≤ 0.05; ▲—statistically significant difference compared with other groups in the presence of glucose, for p ≤ 0.05.

• 

  Figure 2. MCP-1 level in the supernatant from a culture of human PBMCs isolated from statin-treated or statin-free type 2 diabetic patients, or from non-diabetic controls in the medium only, or preincubated with glucose (ANOVA). *—statistically significant difference compared with other groups at basic conditions, for p ≤ 0.05; ▲—statistically significant difference compared with other groups in the presence of glucose, for p ≤ 0.05.

• 

  Figure 3. IL-12 level in the supernatant from a culture of human PBMCs isolated from statin-treated or statin-free type 2 diabetic patients, or from non-diabetic controls in the medium only, or preincubated with glucose (ANOVA). *—statistically significant difference compared with other groups at basic conditions, for p ≤ 0.05; ▲—statistically significant difference compared with other groups in the presence of glucose, for p ≤ 0.05.

• 

  Figure 4. IL-10 level in the supernatant from a culture of human PBMCs isolated from statin-treated or statin-free type 2 diabetic patients, or from non-diabetic controls in the medium only, or preincubated with glucose (ANOVA). *—statistically significant difference compared with other groups at basic conditions, for p ≤ 0.05; ▲—statistically significant difference compared with other groups in the presence of glucose, for p ≤ 0.05.